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http://dx.doi.org/10.10association in the International Genomics of Alzheimer’s Project (IGAP). To identify the biology un-
derlying the disease, we extended these genetic data in a pathway analysis.
Methods: The ALIGATOR and GSEA algorithms were used in the IGAP data to identify associated
functional pathways and correlated gene expression networks in human brain.
Results: ALIGATOR identified an excess of curated biological pathways showing enrichment of as-
sociation. Enriched areas of biology included the immune response (P5 3.27! 10212 after multiple
testing correction for pathways), regulation of endocytosis (P5 1.31! 10211), cholesterol transport
(P5 2.96! 1029), and proteasome-ubiquitin activity (P5 1.34! 1026). Correlated gene expres-
sion analysis identified four significant network modules, all related to the immune response (cor-
rected P 5 .002–.05).
Conclusions: The immune response, regulation of endocytosis, cholesterol transport, and protein
ubiquitination represent prime targets for AD therapeutics.
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Alzheimer’s disease (AD) affects more than five million
Americans: one in eight at the age of .65 years and repre-
sents .60% of the six million dementia cases in Europe
[1–3]. It is the commonest cause of dementia and imposes
a large socioeconomic burden on individuals, their
families, and society. Prevalence is estimated to treble by
2050; thus, understanding the mechanisms underlying this
disease and developing treatments for it are essential. This
study uses the largest genome-wide association study
(GWAS) sample yet assembled for late-onset AD [4] and
is the first to combine GWAS and expression data in a sys-
tematic search for the biological pathways underlying the
genetic susceptibility to this disorder.s of the International Genomics of Alzheimer’s Dis-
P) can be found in the Appendix at the end of this
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16/j.jalz.2014.05.1757Much of our current understanding of the mechanisms
that contribute to AD derives from the genetics of Mendelian
forms of the disease: mutations in APP, PSEN1, and PSEN2
cause early-onset forms of AD and underpin the amyloid
cascade hypothesis [5]. Although amyloid deposition is
diagnostic of AD, its etiologic contribution to the majority
of common late-onset AD (LOAD) is unclear, and therapeu-
tic strategies addressing the amyloid cascade hypothesis
have been unsuccessful [6]. Therefore, other therapeutic av-
enues must be identified and targeted.
LOAD is genetically complex with 56% to 79% herita-
bility [7]. In the Genetic and Environmental Risk in Alz-
heimer’s Disease data set [8], approximately 20% of the
total trait variance was accounted for by single-
nucleotide polymorphisms (SNPs) on the GWAS chip
outside the APOE region [9], with the ε4 allele of the
APOE gene [10] accounting for a similar amount [9,11].
However, a substantial proportion of the genetic variance
of late-onset AD is not accounted for by the 20 susceptibil-
ity genes currently identified [11]. The remaining genetice Alzheimer’s Association.
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small effect that current sample sizes are insufficient to
detect and rare variants, such as the coding variants in
TREM2 [12], that are poorly tagged by common variants
in GWAS panels. In addition, individual genome-wide sig-
nificant (GWS) genes identified in such studies may them-
selves not form good therapeutic targets, and the areas of
biology that they highlight may only give a partial view
of the potential therapeutic landscape. To gain the
maximum useful information about causative pathways
that may underpin LOAD and be prime targets for pharma-
ceutical intervention, we performed a robust pathway and
integrated gene expression analysis using the largest avail-
able GWAS for AD [4].2. Methods
2.1. Samples and genetic data
The sample comprised 17,008 AD cases and 37,646 con-
trol subjects in the primary GWAS analysis, with 8752 AD
cases and 11,312 control subjects in the replication/exten-
sion sample and is described in detail elsewhere [4]. Only
selected SNPs were genotyped in the replication/extension
sample (see Online Methods).2.2. Pathway analyses
We explored whether particular biological pathways were
enriched for genetic associations [13,14] in the International
Genomics of Alzheimer’s Project (IGAP) data [4]. We used
ALIGATOR [13,14] to test whether genes containing signals
below the genome-wide significance threshold contribute to
a pathway signal. ALIGATOR defines significant genes as
having a best single-SNP P value less than a preset
threshold. The resulting list of significant genes is compared
with replicate gene sets generated by sampling SNPs
randomly (thereby correcting for gene size). The method
also controls for linkage disequilibrium (LD) between genes
and multiple testing of nonindependent pathways (see
Online Methods). Brown’s method [15] was used to test
pathway enrichment in the replication data. This method
combines multiple SNPs together, explicitly correcting for
both linkage disequilibrium (LD) between SNPs and theTable 1
Significant excess of enriched pathways remain after removing APOE and the ge
Genes removed (number of genes)
Enrichment P , .05
Number of pathways P
None 542 ,.0002
APOE 1 1 Mb (77) 446 .0002
APOE 1 1 Mb 1 GWS (98) 402 .0020
APOE 1 1 Mb 1 GWS11 Mb (552) 336 .0094
Abbreviations: GWS, genome-wide significant; SNP, single-nucleotide polymo
NOTE. Genes containing a SNPwith P, 8.32! 1024 were counted as significa
when no genes are removed. The zero-kilobase window was used to assign SNPsnumber of SNPs per gene (see Online Methods). Thus,
correction for gene size was applied at both stages of the
analysis. We interrogated the externally curated gene
ontology and KEGG and MSigDB functional pathway col-
lections (see Online Methods).
2.3. Expression correlation analyses
We used the expression data from Gibbs et al. [16] and
performed weighted gene correlation network analysis
(WGCNA) using the WGCNA package [17], separately on
each tissue type to identify clusters of highly correlated
genes called “modules.” These modules were then tested
for enrichment of genome-wide association signal in ALI-
GATOR.3. Results
The sub-GWS variation in the IGAP data contains genetic
signal, manifest by a significant excess of SNPs at all signif-
icance threshold up to P 5 .05 (Supplementary Table 1).
This signal is unlikely to be due to uncorrected stratification
because each of the individual Caucasian GWAS samples in
the IGAP meta-analysis was corrected for ethnic variation
using principal components [18].
We first identified a significant excess of biological
pathways enriched for association signal in the IGAP
data (Table 1 and Supplementary Table 2). Using the
most significant 18,472 SNPs (P , 8.32 ! 1024) from
IGAP [4], covering the top 5% of genes, 177 significantly
enriched (P , .01) curated pathways were identified by
ALIGATOR. To ensure that the excess of pathways was
not an artifact of LD with genes of strong effect, we per-
formed secondary enrichment analyses removing all
genes that lay in the LD region of APOE or any of the
GWS genes from the IGAP [4] study. A significant excess
of enriched pathways remained (Table 1), showing that
the pathways showed significant enrichment independent
of the “known” AD genes. Likewise, a significant excess
of enriched pathways was observed when the P-value cri-
terion for defining significant SNPs and genes was varied
(Supplementary Table 3).
Many of the 177 pathways with P , .01 in ALIGATOR
are still significantly enriched after removing the APOEnome-wide significant genes
Enrichment P , .01 Enrichment P , .001
Number of pathways P Number of pathways P
177 ,.0002 40 ,.0002
131 .0006 28 .0008
116 .0008 23 ,.0002
93 .0066 22 .0018
rphism.
nt. This corresponds to the top 5% of genes (ranked bymost significant SNP)
to genes.
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Supplementary Table 4). They remain significantly enriched
under a range of P-value criteria for defining significant
SNPs and are also significant under a GSEA analysis
[19,20]. This robustness to analysis parameters and
methods gives confidence that the enrichments observed
by ALIGATOR are genuine.
Of the 177 pathways significant at P, .01 in the ALIGA-
TOR analysis of the IGAP GWAS, 119 are significant
(P , .05) in the replication sample. This is more than that
expected by chance (see Online Methods), a further confir-
mation that the pathways highlighted by the ALIGATORTable 2
Clusters of significant pathways in combined IGAP GWAS and replication data (
Cluster Pathway number Number of genes Number of sig P value
1 GO: 2455 32 5 3.27! 1
1 GO:50776 421 29 3.24! 1
1 GO: 2684 421 31 3.95! 1
1 GO:50778 271 21 1.55! 1
1 KEGG 4664 78 13 5.76! 1
2 GO:60627 140 20 1.31! 1
2 GO:30100 88 14 6.76! 1
2 GO:45806 19 6 3.91! 1
2 GO:48261 6 3 3.89! 1
2 GO:48259 30 6 6.19! 1
3 GO:30301 41 8 2.96! 1
3 GO:43691 16 5 3.90! 1
3 GO:15918 42 8 3.91! 1
3 GO:34366 8 2 6.40! 1
4 KEGG 4640 81 11 1.05! 1
5 GO:32434 40 5 1.34! 1
5 GO:51437 70 9 2.60! 1
5 GO:51439 76 9 3.82! 1
5 REACT 440 108 11 3.89! 1
5 GO:51443 77 9 9.62! 1
6 REACT 539 261 25 2.95! 1
7 GO:30131 31 7 1.20! 1
7 GO:30119 32 7 1.53! 1
7 GO:44433 301 31 1.01! 1
7 GO:30122 9 4 1.29! 1
7 GO:30118 39 7 1.35! 1
8 GO: 6457 200 12 1.60! 1
Abbreviations: IGAP, International Genomics of Alzheimer’s Project; GWAS,
NOTE. To obtain themost strongly enriched pathways in the entire data set (IGA
ing the top 5% of genes as significant) were combined with those from the replicati
samples were corrected for multiple testing of 9816 pathways using the Sidak for
number of genes common to both sets divided by the number of genes in the sma
it and the gene sets already in the cluster was greater than 0.4. If it was not possib
procedure was carried out recursively, in descending order of enrichment significa
pathways are significant, only the fivemost significant pathways in each cluster are
analysis of the IGAP GWAS data is given in Supplementary Table 4. “No GWS” re
(P , 5 ! 1028) in the IGAP GWAS data set (and thus expected to be strongly
replication data.analysis contain genuine signals. Notably, pathway SNPs
had significantly lower replication P values than nonpath-
way SNPs even after correcting for their P values in the orig-
inal IGAP GWAS (two-sided P 5 .0237, see Online
Methods). Thus, the pathway analyses highlighted which
among a set of associated, but not GWS, SNPs are likely
to replicate and therefore be enriched for true signals. To
obtain the most strongly enriched pathways in the entire
data set, the P values from the ALIGATOR analysis were
combined with those from the replication study using the
Fisher method and corrected for multiple testing of 9816
pathways using the Sidak formula. Forty-five pathwaysSidak-corrected P value ,.05)
P value no GWS Description
0212 5.72! 1021 Humoral immune response mediated by
circulating immunoglobulin
029 1.57! 1024 Regulation of immune response
029 2.11! 1024 Positive regulation of immune system
process
027 6.65! 1024 Positive regulation of immune response
024 2.18! 1022 Fc epsilon RI signaling pathway
0211 2.00! 1021 Regulation of vesicle-mediated transport
0210 1.06! 1021 Regulation of endocytosis
027 1.77! 1022 Negative regulation of endocytosis
026 9.82! 1021 Negative regulation of receptor-mediated
endocytosis
025 1.00 Regulation of receptor-mediated endocytosis
029 2.51! 1021 Cholesterol transport
029 2.78! 1021 Reverse cholesterol transport
029 3.15! 1021 Sterol transport
027 N/A Spherical high-density lipoprotein particle
028 4.91! 1021 Hematopoietic cell lineage
026 1.00 Regulation of proteasomal ubiquitin-
dependent protein catabolic process
023 2.60! 1023 Positive regulation of ubiquitin-protein ligase
activity involved in mitotic cell cycle
023 3.82! 1023 Regulation of ubiquitin-protein ligase
activity involved in mitotic cell cycle
023 3.89! 1023 REACTOME_CELL_
CYCLE_CHECKPOINTS
023 9.62! 1023 Positive regulation of ubiquitin-protein ligase
activity
025 6.93! 1022 REACTOME_HEMOSTASIS
023 9.13! 1021 Clathrin adaptor complex
023 9.54! 1021 AP-type membrane coat adaptor complex
022 1.00 Cytoplasmic vesicle part
022 1.00 AP-2 adaptor complex
022 1.00 Clathrin coat
023 1.00 Protein folding
genome-wide association study; GWS, genome-wide significant.
P GWAS and replication), theP values from the ALIGATOR analysis (count-
on study using the Fisher method. The resulting P values from the combined
mula. For each pair of gene sets, an overlap measure K was defined as the
ller data set. A gene set was assigned to a cluster if the average K between
le to assign a gene set to an existing cluster, a new cluster was started. This
nce. Clusters containing a significant pathway are listed here, and where.5
shown. A complete list of pathways significant at P, .01 in the ALIGATOR
fers to analyses in which genes containing an SNP genome-wide significant
significant in the replication data set) are removed from the analysis of the
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P, .05) in the combined data set. These pathways are listed
in Table 2, grouped into clusters by gene membership such
that pathways with.40% of genes in common are gathered
in a cluster.
This multiple testing correction may be considered con-
servative because it assumes that the pathways are indepen-
dent, whereas in fact, there is considerable genetic overlap
between them. Sidak-corrected P values for the combined
IGAP GWAS and replication data sets are therefore given
in Supplementary Table 4 for all 177 pathways significant
at P , .01 in the ALIGATOR analysis of the IGAP
GWAS. Redundant pathways (i.e., those with high genetic
overlap with other pathways) were not pruned from our anal-
ysis because it is not clear a priori which pathways will give
the most significant enrichment and should thus be retained.
Pruning a posteriori (i.e., by choosing the most significant
pathways) will bias the significance of the combined discov-
ery and replication P values (making the correction for mul-
tiple testing of pathways anticonservative). The pathway
clusters given in Table 2 and Supplementary Table 4 are in-
tended to aid interpretation of our results in light of shared
gene membership between pathways, by highlighting areas
of biology rather than individual pathways.
The clusters of multiple pathways were related to the
broad categories of immune response, regulation of endo-
cytosis, cholesterol transport, protein ubiquitination, and
clathrin, with the first three of these being particularly
strongly enriched for signal. Because one would expect
SNPs showing strong association to be significant on repli-
cation regardless of biology, the analysis was repeated
removing genes containing a GWS SNP in the IGAP
GWAS from the analysis of the replication data. From
Table 2, it can be seen that the immune-related and ubiqui-
tination pathways are still highly significant. Sidak-Fig. 1. The pathways highlighted by ALIGATOR ontology analyses are related. T
identified in ALIGATOR only. Bubble size (and label font size) reflects the freque
reflects pathway P value. Similar GO terms are linked by edges (lines) in the netwo
line length is arbitrary. Strong relationships are revealed between negative regulat
related to the immune response process.corrected P values for all 177 pathways significant at
P , .01 in the ALIGATOR analysis are shown in
Supplementary Table 4. The relationship between the en-
riched pathways is shown by their shared gene membership
(Fig. 1). Table 3 lists genes in the clusters identified in
Table 2 that are counted as significant (best single-SNP
P , 8.32 ! 1024) in the ALIGATOR analysis of the
IGAP GWAS and also gene-wide significant (gene-wide
P , .05) in both the IGAP GWAS and the replication
data. P values for all genes counted as significant in the
ALIGATOR analysis from the 177 pathways enriched at
P , .01 are given in Supplementary Table 5.
In contrast to ALIGATOR, GSEA uses all genes (rather
than using a threshold) and weights these by their signifi-
cance so may highlight different biological signals. We
therefore performed a secondary analysis of all pathways us-
ing GSEA. Pathways significant under GSEA but not ALI-
GATOR are shown in Supplementary Table 6. Most of
these pathways relate to areas of biology already highlighted
in the ALIGATOR analysis, the exceptions being synapse,
neuronal differentiation, and calcium signaling
(Supplementary Table 6). Genes contributing to these
pathway signals that are significant in both the IGAP
GWAS and the replication studies are listed in
Supplementary Table 7. Notably, these pathways contain
large genes. In addition to the differences between ALIGA-
TOR and GSEA described previously, the Simes correction
for gene size used by GSEA is less stringent for large genes
than that used by ALIGATOR, thereby explaining the
discrepancy in the results between the methods.
In the ALIGATOR analysis, 73.2% of the top 5% of genes
mapped to a pathway, leaving a substantial minority of genes
unannotated: in addition, many annotated genes may possess
other functions not currently annotated. Genes with corre-
lated expression patterns display functional similarities,he network was generated in ReVIGO [32] using gene ontology processes
ncy of the gene ontology (GO) term in the GOA database and bubble color
rk in which line width reflects the degree of similarity between pathways but
ion of endocytosis and cholesterol transport, and many of the pathways are
Table 3
Genes in the significant ALIGATOR pathway clusters
Entrez ID Gene symbol Best P (IGAP) Gene-wide P (IGAP) Best P (REP) Gene-wide P (REP)
Cluster 1: immune response
1191 CLU 2.48! 10217 5.14! 10215 1.06! 10210 2.60! 1028
1378 CR1 3.65! 10215 3.46! 1027 3.82! 10211 5.06! 1028
2206 MS4A2 3.28! 10210 3.68! 1029 1.81! 1024 6.54! 1026
3117 HLA-DQA1 3.38! 1029 1.20! 1025 5.33! 1025 8.89! 1023
3123 HLA-DRB1 1.24! 1028 6.54! 1026 5.80! 1025 1.13! 1022
3127 HLA-DRB5 2.87! 1027 4.78! 1025 4.56! 1024 5.23! 1023
1380 CR2 9.35! 1027 2.99! 1022 5.76! 1025 6.41! 1023
3119 HLA-DQB1 2.97! 1026 3.88! 1025 3.58! 1024 6.45! 1023
3635 INPP5D 6.62! 1026 3.33! 1023 9.93! 1026 1.02! 1024
102 ADAM10 1.45! 1024 2.90! 1022 1.13! 1022 2.71! 1022
Cluster 2: endocytosis
274 BIN1 3.72! 10216 4.75! 1026 3.15! 10211 5.27! 1029
8301 PICALM 1.91! 10212 1.20! 1028 2.57! 1027 2.97! 1027
2206 MS4A2 3.28! 10210 3.68! 1029 1.81! 1024 6.54! 1026
1265 CNN2 1.19! 1026 3.07! 1023 2.91! 1024 2.11! 1023
Cluster 3: cholesterol transport
1191 CLU 2.48! 10217 5.14! 10215 1.06! 10210 2.60! 1028
10,347 ABCA7 1.70! 1029 3.00! 1027 1.43! 1026 1.02! 1026
Cluster 4: hematopoietic cell lineage
1378 CR1 3.65! 10215 3.46! 1027 3.82! 10211 5.06! 1028
3123 HLA-DRB1 1.24! 1028 6.54! 1026 5.80! 1025 1.13! 1022
3127 HLA-DRB5 2.87! 1027 4.78! 1025 4.56! 1024 5.23! 1023
1380 CR2 9.35! 1027 2.99! 1022 5.76! 1025 6.41! 1023
Cluster 5: protein ubiquitination
1191 CLU 2.48! 10217 5.14! 10215 1.06! 10210 2.60! 1028
5702 PSMC3 3.70! 1026 3.04! 1025 1.55! 1022 1.15! 1022
5434 POLR2E 1.94! 1025 6.93! 1023 1.08! 1023 1.26! 1024
6827 SUPT4H1 1.94! 1024 2.26! 1022 2.27! 1022 2.27! 1022
5706 PSMC6 2.98! 1024 1.25! 1022 3.99! 1022 3.79! 1022
6878 TAF6 4.22! 1024 1.66! 1022 6.41! 1024 6.41! 1024
Cluster 6: hemostasis
1191 CLU 2.48! 10217 5.14! 10215 1.06! 10210 2.60! 1028
3635 INPP5D 6.62! 1026 3.33! 1023 9.93! 1026 1.02! 1024
Cluster 7: clathrin/AP2 adaptor complex
1191 CLU 2.48! 10217 5.14! 10215 1.06! 10210 2.60! 1028
8301 PICALM 1.91! 10212 1.20! 1028 2.57! 1027 2.97! 1027
9179 AP4M1 2.16! 1024 2.13! 1023 3.74! 1024 1.57! 1024
Cluster 8: protein folding
1191 CLU 2.48! 10217 5.14! 10215 1.06! 10210 2.60! 1028
664618 HSP90AB4 4.62! 1024 2.30! 1023 2.19! 1022 4.48! 1022
Abbreviation: IGAP, International Genomics of Alzheimer’s Project; REP, replication.
NOTE. Gene-wide P values were calculated using the Brown method (see Online Methods). Genes shown are those counted as significant (best
P , 8.32 ! 1024) in the ALIGATOR analysis of the IGAP GWAS data that are also significant (gene-wide P , .05) in the replication data. Genes in
the vicinity of APOE are not included in this table because this region was not genotyped in the replication sample. Such genes were highly significant
in the meta-analysis (P , 1! 10210) and comprise APOC1/2 in cluster 2; APOE and APOC1/2/4 in cluster 4; APOE, PVRL, BCL3, and PVR in cluster
7; APOE in cluster 8.
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genes as being important in the etiology of LOAD. There-
fore, to overcome the annotation gap and access biologically
related signal across the entire genome, we created modules
of brain co-expressed genes and tested them for enrichment
of association signal in the IGAP GWAS. The data set we
used consisted of gene expression data from four brain re-
gions in a sample of approximately 150 control brains [16]
and was independent from that used by Zhang et al. [21].
We used control individuals rather than AD cases so that cor-relations between expression levels would not be
confounded by neuron loss. AWGCNA [17] gave 117 mod-
ules of co-expressed genes in these data (see OnlineMethods
and Supplementary Table 8): these 117 modules were tested
for enrichment of association signal in the IGAP GWAS us-
ing ALIGATOR. Four modules were found to be signifi-
cantly enriched after correcting for multiple testing, and
these enrichments were robust to varying P-value criteria
and analysis methods (Supplementary Table 9). The four
significantly enriched modules, one from each brain region,
Fig. 2. The immune response is enriched in gene co-expression modules from human brain. (A) Venn diagram indicating the number of genes in common
across the four modules that were found to be significantly enriched in the IGAP GWAS using ALIGATOR after correcting for multiple testing. Each sig-
nificant module originates from a different brain region as indicated here. Colored nodes indicate a multiterm cluster: the related terms represented by each
node are given in B, in increasing significance order. Sources of the functional terms are BP 5 GOTERM_BP_FAT: gene ontology biological processes in
DAVID’s GO Fat Database; CC5GOTERM_CC_FAT: cellular component terms in DAVID’s GO Fat Database; SP5 SP_PIR_KEYWORDS: keywords in
the UniProt (Swiss-Prot/Protein Information Resource) database; SEQ5UP_SEQ_FEATURE: UniProt sequence annotation feature. The full data are avail-
able in Supplementary Table 8. (C) Network showing the pathways significantly enriched for gene membership among the 151 genes present in at least two of
the four most significantly enriched expression modules: the principal biological themes were derived fromDAVID [33,34] analysis. Terms from the analysis
were filtered at 0.05% false discovery Rate (FDR), progressively clustered according to average gene similarity at a threshold of 90% and rendered on
Cytoscape with the Enrichment Map plugin [35,36]. The diagram shows only the principal (lowest FDR) term for each of the clusters, and white nodes
indicate a single term that does not cluster with other groups. (D) Network showing the strongest correlations in expression (.0.9 in at least one brain
area) between genes present in at least two of the four most significantly enriched expression modules. Cb, cerebellum; FC, frontal cortex; TC, temporal
cortex.
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gene membership (Fig. 2).
The extent to which the overlap in gene membership be-
tween these modules is related to the GWAS signal wasinvestigated by examining genes that occurred in multiple
modules and testing these for enrichment using ALIGA-
TOR and GSEA (Supplementary Table 10). It can be seen
that the set of 151 of 294 genes that are present in two or
International Genomics of Alzheimer’s Disease Consortium (IGAP) / Alzheimer’s & Dementia 11 (2015) 658-671664more modules consistently showed the most significant
enrichment of IGAP signal across a variety of test criteria.
Conversely, the set of 143 genes present in only one module
showed no significant enrichment for association signal,
highlighting the utility of using multiple data sets to pro-
duce meaningful co-expression modules. Fig. 2 shows the
strongest correlations (.0.9 in at least one brain area) be-
tween the 151 genes present in two or more modules. It
can be seen that the TYROBP gene highlighted by Zhang
et al. [21] as an important causal regulator is also a hub
gene in this network. Pathways significantly enriched in
the 151 genes present in two or more modules are shown
in Fig. 2, clustered by gene membership. Many of the en-
riched pathways are immune related, but some are related
to fatty acid metabolism and lipoprotein, further corrobo-
rating the results of our analysis of the IGAP GWAS
data. A list of the 151 genes is shown in Supplementary
Table 11.
We also directly tested the modules described by Zhang
et al. [21] for enrichment of association signal in the IGAP
GWAS data (Supplementary Table 12). No single module
was significantly enriched after correction for multiple
testing of modules (“corr P” , .05), but the most signifi-
cantly enriched modules are immune related. Interestingly,
the immune/microglia module highlighted by Zhang et al.
[21] (#1, yellow) did not show significant enrichment for
association signal in the IGAP GWAS under ALIGATOR
analysis, although it did show moderate enrichment under
GSEA. However, the 108 genes common to both this mod-
ule and the set of 151 genes present in two or more of the
four most significantly enriched modules in our analysis
do show enrichment, which becomes progressively more
significant as increasingly stringent criteria are used to
select significant SNPs and genes (Supplementary
Table 13). The genes that are in the Zhang module but
not our set of 151 genes show no significant enrichment
for association signal under either ALIGATOR or GSEA
analysis.4. Discussion
This analysis reveals pathways etiologically related to
AD in addition to those identified previously [14,22]. The
present sample [4] is larger than any used before and was
imputed on a dense reference panel, giving improved
gene coverage, and is therefore likely to be more powerful
to detect real associations than any previous study. A larger
set of pathways has been analyzed than previously and an-
notations have changed, so gene membership of pathways
is not identical to previous studies, although a substantial
proportion of genes still fall into the annotation gap and
are not currently mapped to any pathway. In the present
analysis, we also clustered genes that were within 1 Mb
of each other together in ALIGATOR to prevent counting
a single signal more than once. Secondary analyses were
also performed removing genes in the APOE LD regionand within 1 Mb of the GWS genes. This was done to pre-
vent pathway enrichments being biased by LD between
pathway genes and neighboring genes of strong effect
and to test whether there were significant pathway enrich-
ments independent of “known” AD genes. Such enrich-
ments would increase the interest of novel pathways and
genes highlighted by the main analysis. Despite these dif-
ferences, many of the pathways previously identified [14]
show enrichment in the IGAP data set (Supplementary
Table 14). These include cholesterol transport, immunity,
and the synaptic transmission, cholinergic pathway, the
latter being the target of the cholinesterase class of drugs
widely used in AD.
We used both GWAS and expression data to detect func-
tional pathways associated with AD. ALIGATOR analysis
of combined IGAP-GWAS and replication samples high-
lights four main areas of biology: the immune response,
regulation of endocytosis, cholesterol transport, and pro-
tein ubiquitination. The immune response is particularly
significant in the replication sample, even when GWS
genes from the IGAP GWAS are excluded. The replication
SNPs were not chosen for pathway membership and do not
survey the genome randomly, so the lack of significance in
some pathway clusters once the GWS genes are removed
does not mean that there is no excess signal in these path-
ways: this may simply not have been measured. However,
these data indicate that further genes that are involved in
the immune response are likely to be implicated in
LOAD. Both regulation of endocytosis and cholesterol
transport are functions also implicated by the GWS genes,
whereas the immune response and protein ubiquitination
contain fewer GWS signals [4]. The most significant sig-
nals in the GSEA analysis relate to the same biology but
add some additional categories related to neurologic
biology including the synapse and neuronal projection
development along with calcium-related signaling, not re-
vealed by ALIGATOR. It is notable that these areas of
biology are linked by common gene membership (Fig. 1),
and their interdependence may also be important in suscep-
tibility to AD.
The additional immune response genes implicated in
cluster 1 (Table 3) are plausible AD risk genes: CR2 en-
codes complement receptor 2, which is present on subsets
of B-cells as is the GWS CR1. HLA-DQB1 is in the chro-
mosome 6 HLA locus in common with several GWS loci.
INPP5D is GWS once replication analyses are taken into
account [4]. As well as being annotated as having immune
system activity, ADAM10 has been proposed as a candi-
date a-secretase that cleaves amyloid precursor protein
to prevent the production of b-amyloid [23]. The protein
ubiquitination cluster 5 (Table 3) includes two ATPase
subunits of the 19S proteasome, PSMC3 and PSMC6,
and three proteins involved in transcriptional control,
POLR2E, SUPT4H1, and TAF6. CNN2, encoding calpo-
nin 2, believed to regulate the actin cytoskeleton [24] ap-
pears in the endocytosis cluster, although it can also
International Genomics of Alzheimer’s Disease Consortium (IGAP) / Alzheimer’s & Dementia 11 (2015) 658-671 665regulate phagocytosis in macrophages [25]. The addi-
tional genes from GSEA include CHRNA2 encoding the
neuronal cholinergic receptor, nicotinic, a 2 and RAPSN,
the receptor-associated protein of the synapse, both of
which appear in the synaptic transmission, cholinergic
pathway (Supplementary Table 13). CAV1 encodes caveo-
lin 1, which can interact with apoE [26] and is found in
caveolae, areas of cholesterol-rich lipid raft involved in
endocytosis. CACNA1D encodes the calcium channel,
voltage-dependent, L-type, a 1D subunit, one of a series
of a subunits that confer channel-specific properties; in-
fluences insulin secretion; and is a risk gene for type 2
diabetes [27]. Finally, APP itself is highlighted in this
analysis: it is annotated in both the synapse and neuronal
clusters. Recent findings show that there is at least one
rare protective coding variant in APP seen in late-onset
AD [28], and this signal may reflect this or other rela-
tively rare variants.
Convergent evidence for the importance of the immune
response in AD susceptibility was obtained by performing
WGCNA on expression data from four brain regions. The
four modules that were significantly enriched for associa-
tion in the IGAP GWAS after multiple testing correction
were related to the immune response and shared multiple
genes in common: INPP5D is GWS [4] and was the only
GWS gene found in these modules. The enrichment for as-
sociation was driven by genes that occurred in two or more
of these modules. None of the modules from Zhang et al.
[21] was significantly enriched for genetic association after
multiple testing correction, although the immune-related
modules in their study gave the strongest signal. However,
although the microglia module highlighted by Zhang et al.
[21] did not show significant enrichment for association,
the genes shared in common with our significant expression
modules did, highlighting the utility of using multiple
expression data sets in generating biologically meaningful
modules. The TYROBP gene highlighted by Zhang et al. as
an important causal regulator is also a hub gene in this
network [29].
Regulation of endocytosis, cholesterol transport, and
ubiquitination were not strongly represented in our
WGCNA modules, which may relate to the large size of
the modules and the use of only brain gene expression. In
addition, coordinated gene expression in brain may well
reflect differences in distribution of specific cell types or
subtypes [30]. The brain expression signatures we used
came from nonneurologically compromised brains, but it
is likely that changes in microglial composition or fate in
response to inflammation or infection in these subjects
could propagate such coordinate changes in gene expres-
sion. TREM2 is one of the 151 genes that occur in two or
more expression modules (Fig. 2), and rare variants in
TREM2 are associated with a significant increase in AD
susceptibility [12]. TREM2 regulates the phenotype of mi-
croglia controlling their downstream activation to an in-flammatory or phagocytotic fate, believed to promote or
inhibit AD pathogenesis, respectively [31]. Thus, the
expression signature we detect through genome-wide
association may also be a marker for changes in microglial
phenotypes that act to enhance or inhibit the susceptibility
of individuals to AD.
As the main motivation for genetic analysis of complex
traits is to understand the biology of disease and inform
the search for treatments, interpretation of genetic signals
in a biologically meaningful way is essential. Pathway ana-
lyses that integrate multiple dense sources of data provide a
means of starting to do this. Identifying strong susceptibility
targets also highlights potential drug targets. Although
expression analyses alone can provide important clues about
etiology of disease, integrating them with genetic data that
identify causative factors underlying susceptibility to dis-
ease ensures that the gene expression signatures revealed
are related to disease etiology rather than secondary effects,
making the pathways highlighted by the analysis primary
targets for therapy. This study implicates regulation of endo-
cytosis and protein ubiquitination, in addition to cholesterol
metabolism, as potential therapeutic targets in AD. It
strongly reinforces the critical role of the immune system
in conferring AD susceptibility: gaining a detailed mecha-
nistic understanding of the events within the immune system
that predispose to AD and investigating how to address these
mechanisms should now be a priority for AD research.Acknowledgments
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1. Systematic review: As themainmotivation for genetic
analysis of complex traits is to understand the biology
of disease and inform the search for treatments, inter-
pretation of genetic signals in a biologically meaning-
ful way is essential. Pathway analyses that integrate
multiple dense sources of data provide a means of
starting to do this. Identifying strong susceptibility tar-
gets also highlights potential drug targets.
2. Interpretation: Although expression analyses alone
can provide important clues about etiology of dis-
ease, integrating them with genetic data that identify
causative factors underlying susceptibility to disease
ensures that the gene expression signatures revealed
are related to disease etiology rather than secondary
effects, making the pathways highlighted by the anal-
ysis primary targets for therapy. This study impli-
cates regulation of endocytosis and protein
ubiquitination, in addition to cholesterol metabolism,
as potential therapeutic targets in Alzheimer’s dis-
ease (AD). It strongly reinforces the critical role of
the immune system in conferring AD susceptibility.
3. Future directions: A detailed mechanistic under-
standing of the events within the immune system
that predispose to AD and investigating how to
address these mechanisms should now be a priority
for AD research.References
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